Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T14:26:13.538Z.
Calculation as of: 2026-10-06T14:26:13.538Z.
Quote observation: 2026-10-06T14:25:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b2d28e84da0c930e75004ae600b803967d1975629f72cad3bf33ad83c9831f21
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Eikon Therapeutics, Inc. Common Stock
Market Cap
$411.99M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$406.54M
EBITDA Yield
N/A
TTM Avg
951.70%
3Y Avg
394.96%
5Y Avg
394.96%
Market Cap
$432.69M
EBITDA Yield
231.73%
TTM Avg
150.45%
3Y Avg
150.45%
5Y Avg
150.45%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $411.99M | N/A | N/A | N/A | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $412.27M | N/A | 3.45% | 4.91% | 6.50% |
| Carlsmed, Inc. (CARL)vs › | $408.32M | N/A | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $407.09M | N/A | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $406.54M | N/A | 951.70% | 394.96% | 394.96% |
| Neurogene Inc. (NGNE)vs › | $402.01M | N/A | N/A | N/A | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $425.86M | N/A | N/A | N/A | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $432.69M | 231.73% | 150.45% | 150.45% | 150.45% |
| Assembly Biosciences, Inc. (ASMB)vs › | $437.27M | N/A | N/A | N/A | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $384.04M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
